Nephrocare's IPO: A Healthy Investment Opportunity?
Nephrocare Health Services' IPO received 12% subscription on its first day. The Rs 871-crore IPO offers a combination of fresh shares and an Offer For Sale. Funds raised will aid expansion and debt reduction. The IPO aims to value the Hyderabad-based company at over Rs 4,600 crore.
- Country:
- India
The initial public offering of Nephrocare Health Services, trading under the brand NephroPlus, marked a moderate start with 12% subscription on its debut day, as per NSE data.
Retail investors showed higher interest with a 20% subscription, but institutional buyers exhibited tepid participation, securing just 448 of over 36 lakh reserved shares.
Nephrocare's Rs 871-crore IPO is structured in both fresh issue and offer-for-sale components, with funds designated for clinic expansion, debt servicing, and general business purposes. The issue closes on December 12, ahead of the market debut set for December 17.
(With inputs from agencies.)
- READ MORE ON:
- IPO
- Nephrocare
- NephroPlus
- dialysis
- investment
- shares
- Hyderabad
- expansion
- stock market
- subscription
ALSO READ
Amidst Crisis: Rethinking the 60/40 Investment Strategy
Cyber Fraud Unveiled: Grocery Owner Duped in Stock Investment Scam
PM exhorts industry to step up investment in research and development and focus on quality.
Global Aviation Chaos: Travel Shares Dive Amid Escalating Middle East Conflict
US-China Investment Talks on the Horizon
Google News